Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis

Gerber, 2013, Chapter 8: locally advanced non-Small cell lung cancer Siegel, 2014, Cancer statistics, CA : Cancer J. Clin., 6, 9 Albain, 2009, Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial, Lancet, 374, 379, 10.1016/S0140-6736(09)60737-6 Belani, 2005, Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol, J. Clin. Oncol., 23, 5883, 10.1200/JCO.2005.55.405 Bradley, 2015, Lancet Oncol., 16, 187, 10.1016/S1470-2045(14)71207-0 Hanna, 2008, Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S Oncology, J. Clin. Oncol., 26, 5755, 10.1200/JCO.2008.17.7840 Kelly, 2008, Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023, J. Clin. Oncol., 26, 2450, 10.1200/JCO.2007.14.4824 Ciardiello, 2008, EGFR antagonists in cancer treatment, N. Engl. J. Med., 358, 1160, 10.1056/NEJMra0707704 Murthy, 2004, Participation in cancer clinical trials: race-, sex-, and age-based disparities, JAMA: J. Am. Med. Assoc., 291, 2720, 10.1001/jama.291.22.2720 Lara, 2001, Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment, J. Clin. Oncol., 19, 1728, 10.1200/JCO.2001.19.6.1728 Denicoff, 2013, The national cancer institute-american society of clinical oncology cancer trial accrual symposium: summary and recommendations, J. Oncol. Pract., 9, 267, 10.1200/JOP.2013.001119 Fuks, 1998, A study in contrasts: eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group, J. Clin. Epidemiol., 51, 69, 10.1016/S0895-4356(97)00240-0 Gerber, 2014, Impact of prior cancer on eligibility for lung cancer clinical trials, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju302 Aguilo, 2008, Multiple independent primary cancers do not adversely affect survival of the lung cancer patient, Eur. J. Cardiothorac. Surg., 34, 1075, 10.1016/j.ejcts.2008.08.004 Duchateau, 2005, Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival, Chest, 127, 1152 Lopez-Encuentra, 2007, Carcinoma Cooperative Group of the Spanish Society of, S., Thoracic, Previous tumour as a prognostic factor in stage I non-small cell lung cancer, Thorax, 62, 386, 10.1136/thx.2005.051615 Liu, 2002, Multiple primary malignancies involving lung cancer-clinical characteristics and prognosis, Lung Cancer, 35, 189, 10.1016/S0169-5002(01)00408-1 Massard, 2000, Lung cancer following previous extrapulmonary malignancy, Eur. J. Cardiothorac. Surg., 18, 524, 10.1016/S1010-7940(00)00571-6 Laccetti, 2015, Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual, J. Natl. Cancer Inst., 107, 10.1093/jnci/djv002 Warren, 2002, Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population, Med. Care, 40 Altekruse, 2010 Adamo, 2015 Coyte, 2014, Second primary cancer risk—the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study, BMC Cancer, 14, 272, 10.1186/1471-2407-14-272 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N. Engl. J. Med., 355, 2542, 10.1056/NEJMoa061884 Ahn, 2013, Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer, Clin. Lung Cancer, 10.1016/j.cllc.2013.06.009 Warren, 2008, Evaluation of trends in the cost of initial cancer treatment, J. Natl. Cancer Inst., 100, 888, 10.1093/jnci/djn175 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J. Chronic Dis., 40, 373, 10.1016/0021-9681(87)90171-8 National Cancer Institute Koroukian, 2010, The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study, Health Serv. Res., 45, 265, 10.1111/j.1475-6773.2009.01051.x Horn, 2013, Identifying barriers associated with enrollment of patients with lung cancer into clinical trials, Clin. Lung Cancer, 14, 14, 10.1016/j.cllc.2012.03.008 Levi, 2014, Second primary cancers in the vaud and neuchatel cancer registries, Eur. J. Cancer Prev. de Moor, 2013, Cancer survivors in the United States : prevalence across the survivorship trajectory and implications for care, cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, Am. Soc. Prev. Oncol., 22, 561 Moyer, 2012, Screening for prostate cancer: u.S. preventive services task force recommendation statement, Ann. Intern. Med., 157, 120, 10.7326/0003-4819-157-2-201207170-00459 Sankila, 1998, Survival of patients with colorectal carcinoma: effect of prior breast cancer, J. Natl. Cancer Inst., 90, 63, 10.1093/jnci/90.1.63 Bunn, 2003, Chemotherapy for elderly patients with advanced non-small cell lung cancer, J. Natl. Cancer Inst., 95, 341, 10.1093/jnci/95.5.341